Other functions - preclinical efficacy and intermediate endpoint biomarkers
Ended Awarded Last action
- Contract number
- HHSN261201200013I
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 10 $5,027,799 obligated
Award facts
- Opportunity
-
- N01CN2500278 Solicitation number
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Feb 27, 2012
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Dec 15, 2011
- Combined order value
- $5,027,799 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 51% used
- $9,950,000.00
- Maximum order
- $9,950,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment.
The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of vaccine candidates, drug combinations, and molecular targets for the prevention of lung, pancreatic, and colon cancers. The contracted work is being conducted at OU's facilities in Oklahoma City and involves in vivo studies, biomarker analysis, and other preclinical efficacy assessments. The task orders are priced on a firm-fixed-price basis, with the exception of a few initial orders that utilized cost-no-fee pricing. This IDC supports the NCI's broader mission of advancing cancer prevention and control through the development of innovative interventions.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSN261201200013I?
HHSN261201200013I was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 20, 2012.
How much is contract HHSN261201200013I worth?
Orders under HHSN261201200013I have obligated $5,027,799. HHSN261201200013I's own ceiling is $9,950,000. A single order can be worth up to $9,950,000.
How many orders have been placed under contract HHSN261201200013I?
10 orders have been placed under HHSN261201200013I, the latest on September 18, 2014.
Who can order from contract HHSN261201200013I?
HHSN261201200013I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract HHSN261201200013I part of a contract vehicle?
Yes. HHSN261201200013I is part of Preclinical Efficacy and Intermediate Endpoint Biomarkers.
Was contract HHSN261201200013I competed?
The extent of competition for HHSN261201200013I was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV